EMIT II Plus Barbiturate AssaySpecific for barbiturates—detects broad class of compounds

The EMIT® II Plus Barbiturate Assay is intended for the qualitative and semiquantitative analysis of barbiturates in human urine at a cutoff value of 200 ng/mL or 300 ng/mL.

Request a Quote

Features & Benefits

Barbiturates are a class of nervous-system depressants that are absorbed rapidly and for which 30–40% is bound to plasma protein and the remainder is distributed to muscle, fat, and the liver. They are classified based on their duration of action, ranging from very short-acting (approximately 15 minutes) to long-acting (a day or more). Some of the most commonly abused barbiturates are the short-acting ones, including pentobarbital and secobarbital.

The EMIT II Plus Barbiturate Assay provides:

  • High sensitivity to phenobarbital
  • Excellent precision—all within-lab (total) CVs ≤0.7% or less across the assay range
  • Dual cutoffs available with one assay
  • Ready-to-use liquid reagents, calibrators, and controls
  • >93% correlation to the reference method


Applications are available for the Viva-Jr®, Viva-E®, Viva-ProE®, V-Twin® drug testing systems and AU® Series analyzers.


Technical Specifications

 Assay Principle

  Homogeneous Enzyme Multiplied Immonoassay (EMIT)


  200 ng/mL and 300 ng/mL



 Reagent Stability

  Unopened until expiration date; Onboard instrument: up to 4 weeks

 Calibration Frequency

  As indicated by control results